Blog
Health Canada Compliance Insights
NHPD testing guides, Canadian regulatory updates, and compliance insights for natural health product manufacturers, supplement brands, and Amazon Canada sellers.
Lyophilization Under Canada GMP: What Health Canada Expects From Freeze-Drying Operations
Health Canada GMP requirements for lyophilization: lyophilizer qualification, process validation, and aseptic controls for Canadian pharmaceutical manufacturers.
mRNA Drug Manufacturing Under Canada GMP: What Health Canada's Biologics Framework Actually Requires
Health Canada classifies mRNA drugs as Schedule D biologics — triggering BGTD lot release, Division 2 GMP rules, and ICH Q5 requirements most CMOs aren't ready for.
Probiotics in Canada: How Health Canada Draws the Line Between an NHP and a Drug
How Canada's natural health products regulations determine whether your probiotic needs an NPN or a DIN — and which label claims trigger a drug submission.
Section 56 Exemptions Under Canada's CDSA: What Sponsors and CROs Need to Know Before Starting a Psychedelic Clinical Trial
Psychedelic clinical trials in Canada require both a CTA and a Section 56 CDSA exemption on separate tracks. Here's how to coordinate them and avoid costly delays.
Data Protection for Innovative Drugs in Canada: How the 8-Year Exclusivity Window Actually Works
Section C.08.004.1 of Canada's Food and Drug Regulations grants 8 years of data protection for innovative drugs. Here's how the clock works and who qualifies.
Paper vs. Electronic Lab Notebooks in Canadian GMP Facilities: What Health Canada Actually Expects
Health Canada GMP guidelines set specific expectations for lab records. Here's what electronic lab notebook validation actually requires under Canada GMP.
Canada's Orphan Drug Pathway: What Rare Disease Sponsors Actually Need to Know Before Filing
Canada has no Orphan Drug Act — but rare disease sponsors have Priority Review, NOC/c, and parallel CADTH advice. Here's how the framework actually works.
Drug Establishment Licence Amendments Under Health Canada: When You Need One and How Long It Takes
Learn when a Drug Establishment Licence amendment is required under Health Canada GMP regulations, how to apply, and what timelines to realistically plan for.
Canada's Pharmaceutical Labs Are Understaffed — And GMP Auditors Are Starting to Notice
Canada's analytical chemist shortage isn't just an HR problem — it's creating real GMP compliance risks that Health Canada inspectors are flagging.
Health Canada's NOC/c Pathway: What Sponsors of Serious-Disease Drugs Need to Know Before Filing
Health Canada's NOC/c offers conditional drug approval for serious diseases, with binding post-market commitments. A practical guide for Canadian drug sponsors.
Beyond Health Canada Approval: How CADTH's HTA Process Determines Whether Canadians Can Access Your Drug
A Health Canada NOC is only the first gate. This guide explains CADTH's Common Drug Review, submission requirements, realistic timelines, and what sponsors consistently get wrong.
Decentralized Clinical Trials in Canada: What Health Canada's Guidance Actually Means for Sponsors and CROs
Health Canada permits DCTs under existing regulations — but protocol amendments, eConsent, and data integrity obligations are stricter than most sponsors expect.
Health Canada's Compendium of Monographs: Your Fastest Path to an NPN Under Canada's Natural Health Products Regulations
Learn how to use Health Canada's Compendium of Monographs to qualify for the faster Type I NPN pathway under Canada's Natural Health Products Regulations.
Forced Degradation Studies for Canadian Drug Submissions: What ICH Q1A and Health Canada Actually Require
Learn what Health Canada reviewers expect from forced degradation studies in Module 3 of your CTD, and the three mistakes that reliably delay NDS approval.
Pharmaceutical Water System Qualification Under Canada GMP: What Health Canada Inspectors Expect
What Health Canada GMP inspectors actually look for in pharmaceutical water system qualification — from three-phase PQ to alert limits, sanitization records, and change control.
ICH Q2(R2) Is Now Active: What Canadian Pharmaceutical Labs Need to Update in Their Analytical Validation Packages
ICH Q2(R2) is now active. Canadian pharma labs must update validation packages to meet new ATP and life cycle requirements for Health Canada GMP compliance.
GMP Quality Agreements for Contract Testing Laboratories in Canada: What Health Canada Actually Expects
Health Canada GMP inspectors routinely flag incomplete quality agreements with contract labs. Here's what every Canadian drug manufacturer must include.
Drug Serialization in Canada: The Traceability Requirements Your Pharma Supply Chain Cannot Ignore
Canada has no DSCSA equivalent yet — but Health Canada GMP, US export obligations, and hospital buyer pressure are closing the traceability gap fast.